Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04072237 | Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia | PHASE1 | COMPLETED | 11 | — | — | Sep 1, 2019 | Jun 1, 2020 | Sep 12, 2021 | - | — |
| Name | Type | Description |
|---|---|---|
| MarzAA (marzeptacog alfa [activated]) | BIOLOGICAL | Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant) |